Our new collaboration with Labcorp to develop and commercialize RNA-based oncology diagnostics was recently featured in the Triangle Business Journal. Read more at https://bizj.us/1qcgmk.

DURHAM, N.C. – October 12, 2021 — GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced a new strategic collaboration with Labcorp, a leading global life sciences company, to develop and commercialize new RNA-based gene signatures as diagnostics for people with cancer. This latest collaboration builds on the organizations’ existing […]

Ongoing Collaboration with Basilea Pharmaceutica International Ltd and their Lisavanbulin Clinical Program in Glioblastoma Will Be Highlighted at ASCO DURHAM, NC / ACCESSWIRE / June 2, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually […]

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 9, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung […]

Durham, NC, February 3, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise, announced today the appointment of Philippe Chemla, PhD, MBA,  as Chief Business Officer.  Dr. Chemla has extensive experience across multiple areas of life sciences research and development, with a focus on strategic collaborations and business development. “Philippe brings a strong […]

RNA-based investigation builds on prior bladder cancer research Durham, NC, August 12, 2020 – GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform […]